Search results
Showing 121 to 135 of 175 results for cognitive behaviour therapy
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.
This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS209Show all sections
Sections for QS209
- Quality statements
- Quality statement 1: Preventing type 2 diabetes
- Quality statement 2: Structured education programme
- Quality statement 3: Continuous glucose monitoring for adults on multiple daily insulin injections who cannot self-monitor using capillary blood glucose monitoring
- Quality statement 4: Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose
- Quality statement 5: Treatment with an SGLT2 inhibitor
- Quality statement 6: 9 key care processes
- Quality statement 7: Assessing the risk of diabetic foot problems on admission to hospital
Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)
Evidence-based recommendations on transcutaneous electrical stimulation of the trigeminal nerve for ADHD. This involves a single-use electrode patch stuck to the forehead, which sends small electrical pulses through the skin during sleep.
View recommendations for IPG748Show all sections
This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.
View quality statements for QS23Show all sections
Sections for QS23
- Quality statements
- Quality statement 1: Needle and syringe programmes
- Quality statement 2: Assessment
- Quality statement 3: Families and carers
- Quality statement 4: Blood-borne viruses
- Quality statement 5: Information and advice
- Quality statement 6: Keyworking – psychosocial interventions
- Quality statement 7: Recovery and reintegration
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)
This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.
Endoscopic thoracic sympathectomy for primary facial blushing (IPG480)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.
This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.
View quality statements for QS53Show all sections
Implanted vagus nerve stimulation for treatment-resistant depression (IPG679)
Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.
View recommendations for IPG679Show all sections
Digital technologies for managing non-specific low back pain: early value assessment (HTG712)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.
Resources, case studies and patient decision aids to show how you can use evidence to improve care and services
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)
NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .
even with the most effective current treatment (for example, cognitive behavioural therapies and social network and environment-based...
Is acupuncture effective in reducing alcohol consumption compared with standard care?
acamprosate or naltrexone) and psychological treatments (for example, cognitive behavioural therapies and social network and...
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.